02:47:26 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2023-02-28 10:01:00

The med-tec company PolarCool AB (publ) continues to establish PolarCap® in European professional ice hockey, by signing a two-year agreement with top Swiss club, SC Bern.

PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, as well as other sports with an increased risk of concussion.

In addition to the league-wide agreement with the Swedish Hockey League, PolarCool has agreements with top teams in Finland, Denmark, Norway, Germany and Switzerland. In the Swiss top league, the National League, SC Bern is now the second team to use PolarCap to treat concussions, alongside HC Davos.

The agreement with SC Bern is strategically important for the company's continued establishment in the National League, even if the financial significance of individual agreements is limited. SC Bern will use the PolarCap for the rest of the 2023 season in an initial evaluation period, with the option to continue into a two-year commercial agreement following the season.

SC Bern General Manager Andrew Ebbett comments;

- We now look forward to including PolarCap in our routines around concussions. The scientific evidence is impressive and it's satisfying to now be able to provide improved treatment possibilities to our players.

PolarCool's CEO Erik Andersson comments;

- It is gratifying that SC Bern has chosen to include PolarCap in their management and treatment of concussions. In our goal to establish PolarCap as a treatment within Swiss ice hockey, adding another influential hockey giant as PolarCap users will aid momentum and broaden interest among other clubs.